Plavix Rebates Aim To Stem Market Share Losses After Generic Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis and Bristol-Myers Squibb have initiated a program offering "large" rebates to third-party payers for Plavix to counter generic competition from Apotex, the companies said
You may also be interested in...
Apotex Seeks $4 Bil. Bond From Sanofi/Bristol At Plavix Injunction Hearing
During an Aug. 18 hearing, Apotex says a preliminary injunction should not include a recall of generic clopidogrel.
Apotex Seeks $4 Bil. Bond From Sanofi/Bristol At Plavix Injunction Hearing
During an Aug. 18 hearing, Apotex says a preliminary injunction should not include a recall of generic clopidogrel.
Plavix Hearing Scheduled For Aug. 18 After Sanofi/Bristol File Preliminary Injunction
Apotex launch of generic clopidogrel is the “largest ‘at-risk’ infringing launch of all time,” Sanofi/Bristol court filing claims.